ArticleMicrobiology spectrum2022
The
Article in Microbiology spectrum, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 12 citations in OpenAlex.
- Genomic insights into efflux-mediated biofilm persistence and multidrug resistance in Achromobacter xylosoxidans from cystic fibrosis.Archives of microbiology · 2026Article
- Establishment of a chinchilla model ofMicrobiology spectrum · 2026Article
- Analysis of virulence of the emerging opportunistic human pathogen Achromobacter in a zebrafish embryo model.BMC microbiology · 2026Article
- Article
- From an emerging pathogen to therapeutic challenges: advances inFrontiers in microbiology · 2026Review
- Establishment ofFrontiers in microbiology · 2026Article
- Achromobacter spp.: Emerging pathogens in the cystic fibrosis lung.PLoS pathogens · 2025Article
- Prevalence and variability of siderophore production in theMicrobiology spectrum · 2024Article
- Pathogenesis ofInfection and immunity · 2023Article
- Identification of Virulence Factors Involved in a Murine Model of Severe Achromobacter xylosoxidans Infection.Infection and immunity · 2023Article
- Polymyxin Resistance and Heteroresistance Are Common in Clinical Isolates ofMicrobiology spectrum · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Achromobacter xylosoxidans is an opportunistic pathogen implicated in a wide variety of human infections including the ability to colonize the lungs of cystic fibrosis (CF) patients. The role of A. xylosoxidans in human pathology remains controversial due to the lack of optimized
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.